EBS

Emergent BioSolutions' stock price has been influenced by several events over the past six months. The company's Q1 2026 earnings report showed revenue and EPS surpassing estimates, leading to a stock increase. A new stock repurchase program of up to $50 million was authorized. A lawsuit against the former CEO for insider trading caused a stock slump. The company received approval for an expanded indication of ACAM2000® and secured a long-term strategic manufacturing contract with SAB Biotherapeutics. Over the past year, the stock price has changed by 43.080%, with a 52-week range between $5.305 and $14.060.